CCL5 and central nervous system cancer: CCL5 autocrine signaling in high-grade glioma promoted growth regulation via the mesenchymal (MES) GBM–GSC subtype, which also expresses higher levels of the stemness marker CD44, a nonconventional or “auxiliary receptor” for CCL5 [113].